SG11201908528UA - Novel pd-l1 targeting dna vaccine for cancer immunotherapy - Google Patents

Novel pd-l1 targeting dna vaccine for cancer immunotherapy

Info

Publication number
SG11201908528UA
SG11201908528UA SG11201908528UA SG11201908528UA SG 11201908528U A SG11201908528U A SG 11201908528UA SG 11201908528U A SG11201908528U A SG 11201908528UA SG 11201908528U A SG11201908528U A SG 11201908528UA
Authority
SG
Singapore
Prior art keywords
international
pct
novel
salmonella
english
Prior art date
Application number
Inventor
Heinz Lubenau
Original Assignee
Vaximm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Ag filed Critical Vaximm Ag
Publication of SG11201908528UA publication Critical patent/SG11201908528UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT Hu omit VIII °nolo Oil 1001111 Oil 010110111110 Hs (10) International Publication Number WO 2018/167290 Al (51) International Patent Classification: A61K 39/00 (2006.01) (21) International Application Number: PCT/EP2018/056721 (22) International Filing Date: 16 March 2018 (16.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17161666.7 17 March 2017 (17.03.2017) EP 17188941.3 01 September 2017 (01.09.2017) EP (71) Applicant: VAXIMM AG [CH/CH]; Hochbergerstrasse 60c, 4057 Basel (CH). (72) Inventor: LUBENAU, Heinz; An der Eselshaut 12, 67435 Neustadt an der Weinstrasse (DE). (74) Agent: WALLINGER RICKER SCHLOTTER TOST- MANN; Patent- and Rechtsanwalte Partnerschaft mbB, ZweibriickenstraBe 5-7, 80331 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) O 0\ N 1-1 1-1 0 (57) : The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule \" comprising an expression cassette encoding PD-Ll. In particular, the present invention relates to said attenuated strain of Salmonella 0 for use in the treatment of cancer. (54) Title: NOVEL PD-L1 TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY
SG11201908528U 2017-03-17 2018-03-16 Novel pd-l1 targeting dna vaccine for cancer immunotherapy SG11201908528UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17161666 2017-03-17
EP17188941 2017-09-01
PCT/EP2018/056721 WO2018167290A1 (en) 2017-03-17 2018-03-16 Novel pd-l1 targeting dna vaccine for cancer immunotherapy

Publications (1)

Publication Number Publication Date
SG11201908528UA true SG11201908528UA (en) 2019-10-30

Family

ID=61627121

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908528U SG11201908528UA (en) 2017-03-17 2018-03-16 Novel pd-l1 targeting dna vaccine for cancer immunotherapy

Country Status (13)

Country Link
US (2) US11357842B2 (en)
EP (1) EP3595704A1 (en)
JP (2) JP7247097B2 (en)
KR (1) KR20190125481A (en)
CN (1) CN110430893A (en)
AU (1) AU2018235153A1 (en)
BR (1) BR112019019251A2 (en)
CA (1) CA3056807A1 (en)
IL (1) IL268677A (en)
MX (1) MX2019011026A (en)
RU (1) RU2019132253A (en)
SG (1) SG11201908528UA (en)
WO (1) WO2018167290A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210042655A (en) 2019-10-10 2021-04-20 주식회사 엘지화학 Apparatus for controlling heating pad
CA3162994A1 (en) 2020-01-13 2021-07-22 Vaximm Ag Salmonella-based dna vaccines in combination with an antibiotic
CU20200075A7 (en) 2020-10-22 2022-05-11 Ct Ingenieria Genetica Biotecnologia CHIMERIC ANTIGEN COMPRISING THE EXTRACELLULAR DOMAIN OF PD-L1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE248924T1 (en) * 1991-05-06 2003-09-15 Us Gov Health & Human Serv CARCINOEMBRYONAL ANTIGEN-EXPRESSING RECOMBINANT VIRUSES AND METHODS OF THEIR APPLICATION
KR20110074850A (en) 2008-08-25 2011-07-04 앰플리뮨, 인크. Pd-1 antagonists and methods of use thereof
CN102219860B (en) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc fusion protein and applications thereof
CA2850245C (en) 2011-10-17 2020-04-28 Herlev Hospital Pd-l1 based immunotherapy
RU2636348C2 (en) 2012-07-05 2017-11-22 Ваксимм Аг Dna-vaccine for application in patients with pancreatic cancer
CA2910213A1 (en) * 2013-04-25 2014-10-30 Vaximm Ag Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1
TWI676636B (en) * 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 Virus like particle comprising pd-1 antigen or pd-1 ligand antigen
SG11201604911VA (en) 2013-12-18 2016-07-28 Vaximm Gmbh Novel msln targeting dna vaccine for cancer immunotherapy
JP6670244B2 (en) * 2014-01-07 2020-03-18 バビタ アグラワル Immunomodulatory compositions and uses thereof
US20180153976A1 (en) 2015-06-18 2018-06-07 Vaximm Ag Novel cmv pp65 targeting dna vaccine for cancer immunotherapy
LT3310379T (en) 2015-06-18 2019-12-27 Vaximm Ag Vegfr-2 targeting dna vaccine for combination therapy

Also Published As

Publication number Publication date
AU2018235153A1 (en) 2019-10-31
JP2023021116A (en) 2023-02-09
IL268677A (en) 2019-10-31
RU2019132253A (en) 2021-04-19
CN110430893A (en) 2019-11-08
EP3595704A1 (en) 2020-01-22
CA3056807A1 (en) 2018-09-20
MX2019011026A (en) 2020-12-10
JP7247097B2 (en) 2023-03-28
WO2018167290A1 (en) 2018-09-20
BR112019019251A2 (en) 2020-04-28
JP2020511139A (en) 2020-04-16
US20220273782A1 (en) 2022-09-01
KR20190125481A (en) 2019-11-06
US11357842B2 (en) 2022-06-14
US20200085928A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201809064QA (en) Chimeric neurotoxins
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201408261UA (en) Syringe
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201809625RA (en) 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201408224SA (en) Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201908980PA (en) Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells